LCM
GLUE icon

Laurion Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Laurion Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,252
Closed -$326K – 565
2022
Q1 		$326K Buy
+23,252
New +$323K ﹤0.01% 426

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Laurion Capital Management's GLUE Position: Q2 2022 in Review

Laurion Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2022, closing a stake of 23,252 shares — an estimated $326K sold.

Laurion Capital Management first reported a position in GLUE in Q1 2022 and held it in 1 quarter. The position peaked at $326K in Q1 2022. 57 funds tracked by Wall St. Rank hold GLUE as of Q2 2022.

  • Laurion Capital Management reported no remaining Monte Rosa Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 23,252 Monte Rosa Therapeutics shares in Q2 2022, an estimated $326K.
  • Laurion Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2022 and held it in 1 quarter.
  • Laurion Capital Management's Monte Rosa Therapeutics position peaked at $326K in Q1 2022.
  • 57 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.